Replimune (REPL) announced that it has submitted a biologics license application, or BLA, to the FDA for RP1 in combination with nivolumab for the treatment of adult patients with advanced melanoma who have previously received an anti-PD1 containing regimen. The submission was made under the accelerated approval pathway. The company also announced that the FDA has granted breakthrough therapy designation to RP1 in combination with nivolumab in the same setting.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REPL:
- Replimune Group’s Q3 2024 Financial Highlights
- Replimune Group Navigates Clinical, Regulatory, and Market Challenges Amid Global Uncertainties
- Replimune reports Q2 EPS (68c), consensus (77c)
- REPL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Replimune price target raised to $17 from $14 at JPMorgan
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
